321 related articles for article (PubMed ID: 12926839)
1. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials.
Martinelli Boneschi F; Rovaris M; Johnson KP; Miller A; Wolinsky JS; Ladkani D; Shifroni G; Comi G; Filippi M
Mult Scler; 2003 Aug; 9(4):349-55. PubMed ID: 12926839
[TBL] [Abstract][Full Text] [Related]
2. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
Comi G; Filippi M; Wolinsky JS
Ann Neurol; 2001 Mar; 49(3):290-7. PubMed ID: 11261502
[TBL] [Abstract][Full Text] [Related]
3. Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial.
Johnson KP; Brooks BR; Ford CC; Goodman AD; Lisak RP; Myers LW; Pruitt AA; Rizzo MA; Rose JW; Weiner LP; Wolinsky JS
Mult Scler; 2003 Dec; 9(6):585-91. PubMed ID: 14664471
[TBL] [Abstract][Full Text] [Related]
4. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
[TBL] [Abstract][Full Text] [Related]
5. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
Fox RJ; Miller DH; Phillips JT; Hutchinson M; Havrdova E; Kita M; Yang M; Raghupathi K; Novas M; Sweetser MT; Viglietta V; Dawson KT;
N Engl J Med; 2012 Sep; 367(12):1087-97. PubMed ID: 22992072
[TBL] [Abstract][Full Text] [Related]
6. Spotlight on glatiramer acetate in relapsing-remitting multiple sclerosis.
Simpson D; Noble S; Perry C
BioDrugs; 2003; 17(3):207-10. PubMed ID: 12749757
[TBL] [Abstract][Full Text] [Related]
7. Therapy with glatiramer acetate for multiple sclerosis.
Munari L; Lovati R; Boiko A
Cochrane Database Syst Rev; 2004; (1):CD004678. PubMed ID: 14974077
[TBL] [Abstract][Full Text] [Related]
8. [Long-term effects of glatiramer acetate in multiple sclerosis].
Brochet B
Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
[TBL] [Abstract][Full Text] [Related]
9. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center.
Wolinsky JS; Narayana PA; Johnson KP;
Mult Scler; 2001 Feb; 7(1):33-41. PubMed ID: 11321192
[TBL] [Abstract][Full Text] [Related]
10. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis.
Khan O; Rieckmann P; Boyko A; Selmaj K; Zivadinov R;
Ann Neurol; 2013 Jun; 73(6):705-13. PubMed ID: 23686821
[TBL] [Abstract][Full Text] [Related]
11. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis.
Simpson D; Noble S; Perry C
CNS Drugs; 2002; 16(12):825-50. PubMed ID: 12421116
[TBL] [Abstract][Full Text] [Related]
12. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group.
Johnson KP; Brooks BR; Ford CC; Goodman A; Guarnaccia J; Lisak RP; Myers LW; Panitch HS; Pruitt A; Rose JW; Kachuck N; Wolinsky JS
Mult Scler; 2000 Aug; 6(4):255-66. PubMed ID: 10962546
[TBL] [Abstract][Full Text] [Related]
13. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; OberyƩ J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F;
JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034
[TBL] [Abstract][Full Text] [Related]
14. Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate.
Hennessy B; Zierhut ML; Kracker H; Keenan A; Sidorenko T
Mult Scler Relat Disord; 2022 Aug; 64():103908. PubMed ID: 35803162
[TBL] [Abstract][Full Text] [Related]
15. Benefit-risk analysis of glatiramer acetate for relapsing-remitting and clinically isolated syndrome multiple sclerosis.
Qizilbash N; Mendez I; Sanchez-de la Rosa R
Clin Ther; 2012 Jan; 34(1):159-176.e5. PubMed ID: 22284996
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of clinical trials with copolymer 1 in multiple sclerosis.
La Mantia L; Milanese C; D'Amico R
Eur Neurol; 2000; 43(4):189-93. PubMed ID: 10828647
[TBL] [Abstract][Full Text] [Related]
17. Glatiramer acetate for multiple sclerosis.
La Mantia L; Munari LM; Lovati R
Cochrane Database Syst Rev; 2010 May; (5):CD004678. PubMed ID: 20464733
[TBL] [Abstract][Full Text] [Related]
18. GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis.
Wolinsky JS; Borresen TE; Dietrich DW; Wynn D; Sidi Y; Steinerman JR; Knappertz V; Kolodny S;
Mult Scler Relat Disord; 2015 Jul; 4(4):370-6. PubMed ID: 26195058
[TBL] [Abstract][Full Text] [Related]
19. Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis.
Miller A; Spada V; Beerkircher D; Kreitman RR
Mult Scler; 2008 May; 14(4):494-9. PubMed ID: 18208875
[TBL] [Abstract][Full Text] [Related]
20. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.
Comi G; Martinelli V; Rodegher M; Moiola L; Bajenaru O; Carra A; Elovaara I; Fazekas F; Hartung HP; Hillert J; King J; Komoly S; Lubetzki C; Montalban X; Myhr KM; Ravnborg M; Rieckmann P; Wynn D; Young C; Filippi M;
Lancet; 2009 Oct; 374(9700):1503-11. PubMed ID: 19815268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]